Technical Monograph: Rosuvastatin, Clopidogrel & Aspirin Capsules
In the pharmaceutical industry, the triple combination of Rosuvastatin, Clopidogrel, and Aspirin is known as the “Gold Standard FDC” (Fixed-Dose Combination) for comprehensive cardiovascular protection. At Healthy Life Pharma, we classify this as a Triple-Action Cardioprotective System.
For Healthy Inc, this is a critical 2026 export-grade product, primarily marketed under brand names like Rozat Gold, Razel Gold, or Rosumac Gold. It is the most robust pharmacological “shield” for patients at high risk of fatal cardiac events.
1. Therapeutic Profile: Primary Indications
This capsule is rarely used for primary prevention; it is the mainstay for Secondary Prevention (preventing a second event after the first one has already occurred).
| Indication | Clinical Context | Technical Rationale |
| Acute Coronary Syndrome (ACS) | Heart Attack / Unstable Angina | Stabilizes the heart immediately following an episode to prevent a recurrence. |
| Post-Stent / Angioplasty | PCI Patients | Dual Antiplatelet Therapy (DAPT) is mandatory to prevent “Stent Thrombosis” while the Statin prevents further blockage. |
| Ischemic Stroke | Neurology | Prevents clot-related brain damage in patients with severe carotid artery disease. |
| High-Risk Diabetics | Preventative Care | Used in diabetic patients with hypertension and obesity who show signs of advanced atherosclerosis. |
2. Mechanism: The “Triple-Action” Synergy
Rosuvastatin (10mg/20mg):
Action: Inhibits HMG-CoA reductase.
Role: Aggressively lowers LDL (“Bad Cholesterol”) and stabilizes the arterial plaque so it doesn’t “burst.”
Clopidogrel (75mg):
Action: Binds to P2Y12 ADP receptors on platelets.
Role: Prevents platelets from clumping. It acts as the “first line” of anti-clotting defense.
Aspirin (75mg/150mg):
Action: Inhibits the COX-1 enzyme.
Role: Prevents the production of Thromboxane A2. It provides a “secondary layer” of anti-clotting protection.
Technical USP: Using two antiplatelets (Clopidogrel + Aspirin) is technically known as Dual Antiplatelet Therapy (DAPT). When combined with a high-intensity Statin (Rosuvastatin), it provides the most comprehensive protection available in 2026.
3. The Pharmacist’s “Technical Monitoring”
As a manufacturer at Healthy Inc, your dossiers must emphasize these 2026 safety protocols:
The “perpHect” Dissolution: Because Rosuvastatin is acid-labile and Aspirin is acidic, our Mumbai facility uses Multi-Particulate Pellet Technology or Multilayer Coating. This ensures each drug releases at its specific required $pH$ in the gut without degrading the others.
The Bleeding Risk: With two blood thinners, the risk of GI bleeding is high. It is technically recommended to take this after a meal to protect the stomach lining.
The Surgery Gap: This medication must be stopped 5–7 days before any surgery (including dental work) to prevent uncontrollable bleeding.
The Manufacturer’s Perspective: Technical & Export
From the desk of Nishith Shah:
Market Positioning: In 2026, position this as a “Compliance Miracle.” Taking one “Gold” capsule is 3x more likely to ensure patient adherence than taking three separate pills.
Regulatory Standard: Ensure your 2026 batches are WHO-GMP certified with rigorous dissolution testing at varying $pH$ levels. This is a major selling point for international B2B buyers.
Packaging: We exclusively use Alu-Alu Cold Form Blistering. Aspirin and Clopidogrel are highly sensitive to the humidity levels we see in Mumbai and export destinations; Alu-Alu is the only way to guarantee a 24-36 month shelf life.